Brief: Veru Says Working To Quantify And Evaluate The Impact To Its Reporting Regarding Past Period Research And Development Expenses
Brief: Veru Inc - Previously Issued Consolidated Financial Statements As Of And For Year Ended September 30, 2023 Should No Longer Be Relied Upon
Brief: Veru Q1 Revenue USD 2.1 Million
Veru Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Veru Announces FDA Clearance Of IND Application To Initiate Phase 2B Clinical Trial with Enobosarm
Brief: Veru Submits IND Application to FDA for Development of Enobosarm
Brief: Veru Announces Pricing Of Public Offering Of Common Stock
Brief: Veru Announces Proposed Public Offering Of Common Stock
Veru Inc expected to post a loss of 23 cents a share - Earnings Preview
Veru falls on raising going concern doubts
Brief: Veru Reports Muscle Data From 5 Clinical Studies Of Enobosarm
Brief: Veru Reaches Agreement With FDA On New Phase 3 Clinical Trial For Sabizabulin
Brief: Veru Reports Clinical Data From The Discontinued Artest Study Of Enobosarm
Veru Inc reports results for the quarter ended in June - Earnings Summary
Brief: Veru Q3 Revenue USD 3.3 Million
Veru Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Integral Ad Science Holding, Paratek Pharmaceuticals, Veru
Brief: Veru Inc Files Prospectus Related To Offering, Resale By Selling Shareholder Of Up To An Aggregate Of 5 Million Shares Of Common Stock - SEC Filing
Brief: Veru Inc - On May 12, 2023, Co Entered Into Open Market Sale Agreement